Oruka Therapeutics, Inc. ORKA
104.56 USD +1.70 (+1.65%)
At closeNov 9, 2026, 4:00 PM EST
104.56 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
103.46 Day range 108.08
25.23 52-week range 115.52
- YTD
- +244.97%
- 1 year
- +276.79%
News
benzinga.com Oruka Therapeutics Q3 EPS $(0.63) Misses $(0.60) Estimate Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.60) by 5 percent. This is a 14.55 percent decrease over losses of…
globenewswire.com Oruka Therapeutics to Participate in Multiple Upcoming Conferences MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new…
benzinga.com Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
benzinga.com Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
benzinga.com Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial Oruka Therapeutics reported positive Week 16 Phase 2b data for ORKA-001, showing 61% complete skin clearance in plaque psoriasis patients.
benzinga.com Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday U.S. stocks rose; Dow gained 350 points. Range Resources jumped 15% on EQT acquisition, while Surgery Partners and others posted sharp gains.- benzinga.com Oruka Reports Week 16 Phase 2b Results For ORKA-001 In Plaque Psoriasis, With 61% PASI 100 And 86% PASI 90 Response Rates; ORKA-001 On Track To Advance Into Phase 3 Trials In 1H 2027 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-AContinued favorable safety and tolerability profile consistent with the IL-23p19 classORKA-001 on…
benzinga.com BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.